107,700 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Axa S.A.

Posted by on Mar 1st, 2023

Axa S.A. acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 107,700 shares of the company’s stock, valued at approximately $908,000. Axa S.A. owned approximately 0.22% of Protagonist Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. UBS Oconnor LLC raised its stake in shares of Protagonist Therapeutics by 5.9% in the 3rd quarter. UBS Oconnor LLC now owns 232,820 shares of the company’s stock valued at $1,963,000 after acquiring an additional 13,000 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Protagonist Therapeutics in the 3rd quarter valued at approximately $1,612,000. New York State Common Retirement Fund raised its stake in shares of Protagonist Therapeutics by 24.2% in the 3rd quarter. New York State Common Retirement Fund now owns 27,697 shares of the company’s stock valued at $233,000 after acquiring an additional 5,397 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in Protagonist Therapeutics in the 3rd quarter valued at approximately $343,000. Finally, Jump Financial LLC grew its holdings in Protagonist Therapeutics by 3.8% in the 3rd quarter. Jump Financial LLC now owns 53,190 shares of the company’s stock valued at $449,000 after buying an additional 1,926 shares during the last quarter. 91.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PTGX. BTIG Research lowered their target price on Protagonist Therapeutics to $41.00 in a report on Wednesday, November 16th. HC Wainwright decreased their price objective on Protagonist Therapeutics from $50.00 to $33.00 and set a “buy” rating on the stock in a report on Thursday, November 10th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.50.

Protagonist Therapeutics Stock Down 0.3 %

PTGX stock opened at $16.22 on Wednesday. The company has a market cap of $798.02 million, a P/E ratio of -6.05 and a beta of 2.11. Protagonist Therapeutics, Inc. has a twelve month low of $6.91 and a twelve month high of $27.97. The business has a fifty day moving average of $13.30 and a 200-day moving average of $10.19.

Protagonist Therapeutics Profile

(Get Rating)

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Read More

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.